OTC$AIM
AIM ImmunoTech Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
AIM ImmunoTech reported a narrower net loss and reduced operating expenses in Q1 2025.
AIM ImmunoTech's Q1 2025 results showed a significant reduction in net loss and operating expenses, despite a decline in revenue. The company faces potential delisting from the NYSE American due to non-compliance with stockholders' equity requirements.
- Net loss decreased to $3.705 million from $5.817 million year-over-year.
- Revenue declined to $16,000 from $40,000 in Q1 2024.
- Research and development expenses reduced to $1.08 million from $1.951 million.
- General and administrative expenses decreased to $2.545 million from $3.815 million.
Headline financials
Revenue & EPS history
AIM ImmunoTech · Revenue · Quarterly
$16K
Forward guidance
AIM ImmunoTech is actively pursuing strategies to regain compliance with NYSE American listing requirements and secure additional funding to support its operations.
Tailwinds
- Net loss reduced significantly year-over-year.
- Decreased R&D and G&A expenses indicate improved cost management.
- Company is exploring various funding sources, including equity offerings.
- Engaged in a forbearance agreement providing temporary financial relief.
- Focused on advancing clinical trials for Ampligen.
Headwinds
- Revenue declined compared to the same quarter last year.
- Cash and cash equivalents decreased, raising liquidity concerns.
- Potential delisting from NYSE American due to non-compliance.
- Working capital deficit indicates short-term financial challenges.
- Stockholders' equity below minimum requirements for continued listing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+20.2%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-10.3%
Avg return
30 days after
50%
30 / 60 earnings
Positive
+946.2%
Q3 2011
Best reaction
-18.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | — | — | |
| Q4 2025 | -18.8% | -30.6% | -38.8% | |
| Q3 2025 | -7.6% | -4.9% | -5.6% | |
| Q2 2025 | +3.1% | -3.5% | +1.2% | |
| Q1 2025 | +0.0% | +0.0% | -25.6% | |
| Q4 2024 | +2.2% | -25.0% | -33.3% | |
| Q3 2024 | -8.8% | -20.0% | -12.0% | |
| Q2 2024 | +7.4% | +14.8% | +11.1% | |
| Q1 2024 | +0.9% | +2.5% | +12.5% | |
| Q4 2023 | -2.8% | +0.0% | -18.4% | |
| Q3 2023 | +7.3% | +2.3% | +20.5% | |
| Q2 2023 | -9.3% | -10.1% | -7.2% | |
| Q1 2023 | -3.5% | +6.8% | +4.5% | |
| Q4 2022 | +3.6% | +0.0% | +11.6% | |
| Q3 2022 | +1.0% | +0.0% | -27.1% | |
| Q2 2022 | -3.8% | -7.8% | -16.9% | |
| Q1 2022 | +2.4% | -7.3% | -8.3% | |
| Q4 2021 | -1.9% | +1.9% | -2.8% | |
| Q3 2021 | -7.0% | -14.6% | -35.1% | |
| Q2 2021 | -2.5% | -3.0% | -2.5% | |
| Q1 2021 | +3.0% | +5.0% | -98.9% | |
| Q4 2020 | +11.7% | +8.9% | +0.9% | |
| Q3 2020 | +6.3% | +3.7% | -3.7% | |
| Q2 2020 | +0.4% | -5.9% | -22.7% | |
| Q1 2020 | +8.9% | +4.7% | +10.2% | |
| Q4 2019 | +9.8% | +2.6% | -21.8% | |
| Q3 2019 | -5.6% | -8.2% | -8.2% | |
| Q2 2019 | +2.2% | +3.8% | +1.1% | |
| Q1 2019 | -6.7% | -13.3% | -23.0% | |
| Q4 2018 | +0.0% | -6.2% | +31.3% | |
| Q3 2018 | +0.0% | -9.1% | -13.6% | |
| Q2 2018 | -6.7% | -13.3% | -23.3% | |
| Q1 2018 | +0.0% | +3.3% | +0.0% | |
| Q4 2017 | +12.5% | +2.5% | -20.0% | |
| Q3 2017 | +0.0% | +0.0% | -3.1% | |
| Q2 2017 | +0.0% | -2.4% | -22.0% | |
| Q1 2017 | -6.3% | -17.2% | -18.8% | |
| Q4 2016 | +5.7% | +0.0% | +26.4% | |
| Q3 2016 | -2.2% | -9.9% | -11.0% | |
| Q1 2016 | +9.1% | — | — | |
| Q4 2015 | +8.3% | — | — | |
| Q3 2015 | +7.1% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | -4.9% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | -7.7% | — | — | |
| Q1 2013 | +0.3% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | +281.0% | — | — | |
| Q2 2012 | +0.5% | — | — | |
| Q1 2012 | -1.9% | — | — | |
| Q4 2011 | +1.9% | — | — | |
| Q3 2011 | +946.2% | — | — | |
| Q2 2011 | -13.4% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q2 2010 | +0.6% | — | — | |
| Q1 2010 | +3.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro